{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.001","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.19","value":"-0.85"},{"groupId":"OG001","spread":"1.34","value":"-1.53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"174"}],"units":"Participants"}],"description":"DAS28 consisted of composite score of following variables: TJC28, SJC28, hsCRP (mg/mL), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-CRP=0.56\\*square root (sqrt)(TJC28)+0.28\\*sqrt(SJC28)+0.36\\*natural log(CRP+1)+0.014\\*Patient's Global VAS+0.96. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"}],"paramType":"MEAN","populationDescription":"mITT population includes all randomized participants who received at least 1 dose of the study drug. Participants were analyzed according to the study drug to which they were randomized. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using mBOCF.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12","title":"Change From Baseline in the DAS28 - hsCRP - Placebo Versus Baricitinib 2 mg","type":"SECONDARY","unitOfMeasure":"Units on a Scale"}